Official Title
Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome
Phase
Phase 4Lead Sponsor
Centro Hospitalario La ConcepcionStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Acute Coronary SyndromeIntervention/Treatment
Chewed ticagrelor Swallowed ticagrelorStudy Participants
50The study aims to determine the pharmacodynamic performance in the first hour measured with verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention
Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff. Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed
Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water. Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed
Inclusion Criteria: All patients presenting to the emergency department with acute coronary syndrome for percutaneous coronary intervention Exclusion Criteria: Age <18 years Known coagulopathy, bleeding diathesis, or active bleeding History of recent gastrointestinal or genitourinary bleeding within 2 months Previous therapy with clopidogrel, prasugrel, or ticagrelor Previous treatment with glycoprotein IIb/IIIa inhibitors or during interventional procedure Major surgery within 6 weeks History of intracranial bleeding or intracraneal neoplasm Suspected aortic dissection Chronic obstructive pulmonary disease Severe hemodynamic instability or cardiogenic shock Resuscitated cardiac arrest Use of vitamin K anticoagulants or novel oral anticoagulants (NOACs) within 7 days Life expectancy <1 year Known severe liver or renal disease, GFR estimated by CKD-EPI <30 ml/min/1.73 m2 Known HIV treatment Hemoglobin <10 g/dL Platelet count <100,000/L Pregnancy Known allergy to ticagrelor Refusal to sign informed consent
